Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company based in Turku, Finland, has published its financial reporting calendar for 2027. The company confirmed that its full-year 2026 financial statement release and Annual Report will be published on 3 March 2027, with a half-year report to follow on 26 August 2027. The Annual General Meeting is planned for 30 March 2027, with a separate stock exchange notice to be issued by the Board of Directors to convene the meeting.

Key Points

  • Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON)
  • Full-year 2026 financial statement release and Annual Report scheduled for 3 March 2027
  • Half-year financial report covering January to June 2027 due 26 August 2027; AGM planned for 30 March 2027
  • Investors may be watching for clinical and financial updates on lead asset bexmarilimab at the full-year results release

Faron Confirms 3 March 2027 as Full-Year 2026 Results Date

The announcement states that Faron Pharmaceuticals will release its full-year 2026 financial statements alongside its Annual Report on 3 March 2027. This is the primary reporting event in the 2027 calendar and will represent the company's most comprehensive financial disclosure of the year. As a clinical-stage biopharmaceutical company, Faron does not generate product revenues in the conventional sense, meaning investors will likely scrutinise cash runway, research and development expenditure, and progress updates on its ongoing clinical programmes when the results are published.

AGM Planned for 30 March 2027 Following Annual Report Publication

Faron's Board of Directors has confirmed that the Annual General Meeting is planned to be held on 30 March 2027, following the publication of the Annual Report earlier in the month. The company notes that a separate stock exchange notice will be issued to formally convene the meeting. The AGM will provide shareholders with an opportunity to engage with the Board on strategic matters, including the development of bexmarilimab, Faron's lead investigational immunotherapy asset, which is currently being evaluated in Phase 1/2 clinical trials.

Bexmarilimab Targets Clever-1 to Reprogram the Tumour Microenvironment

Faron's lead asset, bexmarilimab, is a proprietary, investigational anti-Clever-1 humanised antibody designed to overcome resistance to existing cancer treatments. The announcement states that bexmarilimab binds to Clever-1, a receptor on immunosuppressive macrophages that enables cancer cells to evade the immune system. By targeting this receptor, bexmarilimab is designed to reprogram myeloid cell function and stimulate an anti-tumour immune response. The asset is currently being investigated in Phase 1/2 trials across both haematological cancers and solid tumours in combination with standard-of-care treatments.

Half-Year 2027 Report Scheduled for 26 August

Alongside the full-year results date, Faron has confirmed that its half-year financial report, covering the period from 1 January to 30 June 2027, will be released on 26 August 2027. This interim disclosure will allow investors to assess Faron's operational and financial position at the mid-point of the year. As a dual-listed clinical-stage company on both the London AIM market and Nasdaq First North in Finland, Faron is subject to reporting obligations across both exchanges, and the structured calendar provides stakeholders with clear visibility of upcoming disclosure dates.